7-甲氧基-4-氧代-1,4-二氢-喹啉-2-羧酸甲酯 | 77474-23-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 7-甲氧基-4-氧代-1,4-二氢-喹啉-2-羧酸甲酯
• 中文别名: 4-羟基-7-甲氧基喹啉-3-羧酸甲酯
• 英文名称: 7-methoxy-4-hydroxy-2-methoxycarbonylquinoline
• 英文别名: methyl 4-hydroxy-7-methoxyquinoline-2-carboxylate；2-methoxycarbonyl-4-hydroxy-7-methoxyquinoline；2-carbomethoxy-4-hydroxy-7-methoxyquinoline；7-Methoxy-4-oxo-1,4-dihydro-quinoline-2-carboxylic acid methyl ester；methyl 7-methoxy-4-oxo-1H-quinoline-2-carboxylate
• CAS: 77474-23-8；259214-73-8
• 化学式: C₁₂H₁₁NO₄
• 分子量: 233.224
• InChiKey: MUJXVVHLAUTTHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  7-甲氧基-4-氧代-1,4-二氢-喹啉-2-羧酸甲酯 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-(diaminomethylidene)-4-ethoxy-7-methoxyquinoline-2-carboxamide
  参考文献：
  名称：

  Synthesis and evaluation of quinoline carboxyguanidines as antidiabetic agents

  摘要：

  The synthesis and in vivo activities of a series of substituted quinoline carboxyguanidines as a possible novel class of antidiabetic agents is described. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00354-1
• 作为产物：
  描述：

  (Z)-2-(3-Methoxy-phenylamino)-but-2-enedioic acid dimethyl ester 以 二苯醚 为溶剂， 以64%的产率得到7-甲氧基-4-氧代-1,4-二氢-喹啉-2-羧酸甲酯
  参考文献：
  名称：

  Synthesis and evaluation of quinoline carboxyguanidines as antidiabetic agents

  摘要：

  The synthesis and in vivo activities of a series of substituted quinoline carboxyguanidines as a possible novel class of antidiabetic agents is described. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00354-1

文献信息

• Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
  申请人：Lynch K. John

  公开号：US20050209274A1

  公开（公告）日：2005-09-22

  The present invention is directed to compounds of formula (I), which antagonize of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.

  本发明涉及式(I)的化合物，通过对抗黑素浓集激素（MCH）的作用，通过对抗黑素浓集激素受体，有助于预防或治疗进食障碍、体重增加、肥胖、生殖和性行为异常、甲状腺激素分泌、利尿和水/电解质稳态、感觉处理、记忆、睡眠、觉醒、焦虑、抑郁、癫痫、神经退行性疾病和精神障碍。
• [EN] HEPATITIS C INHIBITOR COMPOUNDS<br/>[FR] COMPOSES INHIBITEURS DE L'HEPATITE C
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2004103996A1

  公开（公告）日：2004-12-02

  Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.

  公式（I）的化合物：其中B、X、R3、L0、L1、L2、R2、R1和RC的定义如本文所述。这些化合物可用作丙型肝炎病毒NS3蛋白酶的抑制剂，用于治疗丙型肝炎病毒感染。
• Hepatitis C inhibitor tri-peptides
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20030187018A1

  公开（公告）日：2003-10-02

  Disclosed herein are compounds of formula (1): 1 wherein R 1 is hydroxy or NHSO 2 R 1A wherein R 1A is (C 1-8 )alkyl, (C 3-7 )cycloalkyl or {(C 1-6 )alkyl-(C 3-7 )cycloalkyl}, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O—(C 1-6 )alkyl, amido, amino or phenyl, or R 1A is C 6 or C 10 aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C 1-6 )alkyl, O—(C 1-6 ) alkyl, amido, amino or phenyl; R 2 is (C 4-6 )cycloalkyl; R 3 is t-btuyl or (C 5-6 ) cycloalkyl and R 4 is (C 4-6 )cycloalkyl; or a pharmaceutically acceptable salt thereof. The compounds are useful as inhibitors of HCV NS3 protease.

  本文揭示了式（1）的化合物： 其中R1是羟基或NHSO2R1A，其中R1A是（C1-8）烷基，（C3-7）环烷基或{（C1-6）烷基-（C3-7）环烷基}，这些都可以选择性地用卤素，氰基，硝基，O-（C1-6）烷基，酰胺，氨基或苯基取代1至3次，或者R1A是C6或C10芳基，该芳基可以选择性地用卤素，氰基，硝基，（C1-6）烷基，O-（C1-6）烷基，酰胺，氨基或苯基取代1至3次；R2是（C4-6）环烷基；R3是叔丁基或（C5-6）环烷基，R4是（C4-6）环烷基；或其药学上可接受的盐。这些化合物可用作HCV NS3蛋白酶的抑制剂。
• Macrocyclic peptides active against the hepatitis C virus
  申请人：Boehringer Ingelheim (Canada) Ltd.

  公开号：US20030224977A1

  公开（公告）日：2003-12-04

  Compounds of formula I: 1 wherein R 1 is hydroxy or NHSO 2 R 1A wherein R 1A is (C 1-8 )alkyl, (C 3-7 )cycloalkyl or {(C 1-6 )alkyl-(C 3-7 )cycloalkyl}, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O(C 1-6 )alkyl, amido, amino or phenyl, or R 1A is C 6 or C 10 aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C 1-6 )alkyl, O(C 1-6 )alkyl, amido, amino or phenyl; R 2 is (C 5-6 )cycloalkyl and R 3 is cyclopentyl; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.

  式I的化合物：其中R1是羟基或NHSO2R1A，其中R1A是（C1-8）烷基，（C3-7）环烷基或（C1-6）烷基-（C3-7）环烷基，这些都可以选择地被卤素，氰基，硝基，O（C1-6）烷基，酰胺基，氨基或苯基取代1到3次，或者R1A是C6或C10芳基，它可以选择地被卤素，氰基，硝基，（C1-6）烷基，O（C1-6）烷基，酰胺基，氨基或苯基取代1到3次；R2是（C5-6）环烷基，R3是环戊基；或其药用可接受的盐，用作HCV NS3蛋白酶的抑制剂。
• Platelet adenosine diphosphate receptor antagonists
  申请人：Schering Aktiengesellschaft

  公开号：US20030060474A1

  公开（公告）日：2003-03-27

  Compounds of the following formula (I): 1 where a, b, R 1 , R 2 , R 4 and R 6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.

  以下公式（I）的化合物：其中a、b、R1、R2、R4和R6如下所述，可用作抑制血小板腺苷二磷酸的药物。本文还描述了含有这些化合物的药物组合物，使用这些化合物作为抗血栓药物的方法以及合成这些化合物的过程。